Posts Tagged ‘Featured’

Glycovax Pharma Inc. is starting the large-scale production of a new glycolipidic vaccine adjuvant developed by the National Research Council of Canada (NRC). The NRC license has allowed Glycovax to optimize SLA manufacturing by developing a fully synthetic process meeting Good Manufacturing Practices (GMP). Continue reading…

Pharma Glycovax will participate, from June 16 to 19, 2025, in the BIO International Convention, at the Boston Convention and Exhibition Center, the largest and most comprehensive event for the full ecosystem of biotech with 20,000 industry leaders from across the globe. https://convention.bio.org/bio-2025